Literature DB >> 29696964

Current therapies and targets for type 2 diabetes mellitus.

Dinesh K Chellappan1, Wei S Yap2, Nurfatihah A Bt Ahmad Suhaimi2, Gaurav Gupta3, Kamal Dua4.   

Abstract

The prevalence of type 2 diabetes mellitus (T2DM) has been increasing at an alarming rate. With an increased understanding of the pathophysiology and pathogenesis of T2DM, various new therapeutic options have been developed to target different key defects in T2DM. Incremental innovations of existing therapies either through unprecedented drug combinations, modified drug molecules, or improved delivery systems are capable to nullify some of the undesirable side effects of traditional therapies as well as to enhance effectiveness. The existing administration routes include inhalation, nasal, buccal, parenteral and oral. Newer drug targets such as protein kinase B (Akt/PKB), AMP-activated protein kinase (AMPK), sirtuin (SIRT), and others are novel approaches that act via different mechanisms and possibly treating T2DM of distinct variations and aetiologies. Other therapies such as endobarrier, gene therapy, and stem cell technology utilize advanced techniques to treat T2DM, and the potential of these therapies are still being explored. Gene therapy is plausible to fix the underlying pathology of T2DM instead of using traditional reactive treatments, especially with the debut of Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR associated protein9 (CRISPR-Cas9) gene editing tool. Molecular targets in T2DM are also being extensively studied as it could target the defects at the molecular level. Furthermore, antibody therapies and vaccinations are also being developed against T2DM; but the ongoing clinical trials are relatively lesser and the developmental progress is slower. Although, there are many therapies designed to cure T2DM, each of them has their own advantages and disadvantages. The preference for the treatment plan usually depends on the health status of the patient and the treatment goal. Therefore, an ideal treatment should take patient's compliance, efficacy, potency, bioavailability, and other pharmacological and non-pharmacological properties into account.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29696964     DOI: 10.23736/S0031-0808.18.03455-9

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  6 in total

1.  Pharmacodynamics and pharmacokinetics of a new type of recombinant insulin Lisargine injection.

Authors:  Jiangjie Lu; Yong Zeng; Xiulin Yi; Hongmei Zhang; Lin Zhu; Lixin Jiang; Jing Li; Wei Zhou; Hong Zhu; Aijun Xiong
Journal:  BMC Complement Med Ther       Date:  2020-11-09

2.  Sirt6 Deacetylase: A Potential Key Regulator in the Prevention of Obesity, Diabetes and Neurodegenerative Disease.

Authors:  Swapnil Raj; Liston Augustine Dsouza; Shailendra Pratap Singh; Abhinav Kanwal
Journal:  Front Pharmacol       Date:  2020-12-07       Impact factor: 5.810

3.  Comparative Analysis of the Therapeutic Effects of Amniotic Membrane and Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Type 2 Diabetes.

Authors:  Zhifeng Wang; Haisen Li; Jingmeng Fang; Xiaoyu Wang; Shuhang Dai; Wei Cao; Yinhong Guo; Zhe Li; Hao Zhu
Journal:  Stem Cell Rev Rep       Date:  2022-01-11       Impact factor: 6.692

4.  Discovery of Phenolic Glycoside from Hyssopus cuspidatus Attenuates LPS-Induced Inflammatory Responses by Inhibition of iNOS and COX-2 Expression through Suppression of NF-κB Activation.

Authors:  Xingyu Liu; Jie Su; Geng Wang; Lihua Zheng; Guannan Wang; Ying Sun; Yongli Bao; Shuyue Wang; Yanxin Huang
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

Review 5.  Role of platelet rich plasma mediated repair and regeneration of cell in early stage of cardiac injury.

Authors:  Syed Sarim Imam; Fahad A Al-Abbasi; Salman Hosawi; Muhammad Afzal; Muhammad Shahid Nadeem; Mohammed M Ghoneim; Sultan Alshehri; Sami I Alzarea; Ali Alquraini; Gaurav Gupta; Imran Kazmi
Journal:  Regen Ther       Date:  2022-02-15       Impact factor: 3.419

6.  Potential antidiabetic activity of benzimidazole derivative albendazole and lansoprazole drugs in different doses in experimental type 2 diabetic rats

Authors:  Burak Dik; Devran Coşkun; Emre Bahçivan; Kamil Üney
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.